Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Acorda Therapeutics Inc

ACOR
Current price
10.32 USD +0.29 USD (+2.91%)
Last closed 9.8 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 12 135 318 USD
Yield for 12 month +1 587.96 %
Week
Month
Year
ACOR
21.11.2021 - 28.11.2021

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. Address: 420 Saw Mill River Road, Ardsley, NY, United States, 10502

Analytics

WallStreet Target Price

10 USD

P/E ratio

3.7433

Dividend Yield

1.86 %

Current Year

+118 566 000 USD

Last Year

+129 071 000 USD

Current Quarter

+27 715 000 USD

Last Quarter

+29 675 000 USD

Current Year

+88 234 000 USD

Last Year

+88 284 000 USD

Current Quarter

+24 328 000 USD

Last Quarter

+26 610 000 USD

Key Figures ACOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 11 505 000 USD
Operating Margin TTM -27.86 %
PE Ratio 3.7433
Return On Assets TTM -3.32 %
PEG Ratio 0.51
Return On Equity TTM -23.68 %
Wall Street Target Price 10 USD
Revenue TTM 111 118 000 USD
Book Value 47.47 USD
Revenue Per Share TTM 87.94 USD
Dividend Share
Quarterly Revenue Growth YOY -17.3 %
Dividend Yield 1.86 %
Gross Profit TTM 82 430 000 USD
Earnings Share 2.61 USD
Diluted Eps TTM 2.61 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY 587.3 %
Profit Margin -14.36 %

Dividend Analytics ACOR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 1.86 %
Last Split Factor 1:20
Payout Ratio
Last Split Date 05.06.2023
Dividend Date 04.01.2021

Stock Valuation ACOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 3.7433
Forward PE
Enterprise Value Revenue 1.4973
Price Sales TTM 0.1079
Enterprise Value EBITDA -14.6965
Price Book MRQ 0.1677

Financials ACOR

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ACOR

For 52 weeks

8.98 USD 24.2 USD
50 Day MA 11.4 USD
Shares Short Prior Month 14 569
200 Day MA 13.21 USD
Short Ratio 1.43
Shares Short 13 198
Short Percent 1.07 %